REMD-477
Drug timelines are a Plus or Pro feature.
4 regulatory and trial events tracked for REMD-477, covering 2017-02-07 to 2024-08-09. Get the full timeline:
Most recent: Clinical Trial Update: Effect of Novel Glucagon Receptor Antagonist REMD-477 on Glucose and Adipocyte Metabolism in T2DM [EARLY_Phase 1]